

**Listing of Claims:**

What is claimed is:

1-7. (Cancelled)

8. (Previously Presented) A method of promoting oligodendrocyte survival in a human suffering from stroke, which comprises administering to said human a therapeutically effective amount of an altered anti-myelin associated glycoprotein (anti-MAG) antibody or functional fragment thereof, wherein the altered antibody or functional fragment thereof binds to MAG and comprises:

a heavy chain variable domain ( $V_H$ ) which comprises in sequence hypervariable regions CDRH1 (SEQ ID NO: 4), CDRH2 (SEQ ID NO: 5), and CDRH3 (SEQ ID NO: 6)

and

a light chain variable domain ( $V_L$ ) which comprises in sequence hypervariable regions CDRL1 (SEQ ID NO: 1), CDRL2 (SEQ ID NO: 2), and CDRL3 (SEQ ID NO: 3).

9. (Previously Presented) A method according to claim 8, wherein the altered anti-MAG antibody or functional fragment thereof comprises at least one variable domain selected from the group consisting of: a heavy chain with an amino acid sequence comprising SEQ ID NO: 7, a heavy chain with an amino acid sequence comprising SEQ ID NO: 9, and a light chain with an amino acid sequence comprising SEQ ID NO: 8.
10. (Previously Presented) A method according to claim 8, wherein the altered anti-MAG antibody or functional fragment thereof comprises at least one heavy chain variable region selected from the group consisting of: SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13 and a light chain variable region selected from the group consisting of: SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17.
11. (Previously Presented) A method according to claim 10, wherein the altered anti-MAG antibody or functional fragment thereof comprises a heavy chain variable region comprising SEQ ID NO: 10 and a light chain variable region

comprising a sequence selected from the group consisting of: SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17.

12. (Previously Presented) A method according to claim 10, wherein the altered anti-MAG antibody or functional fragment thereof comprises a heavy chain variable region comprising SEQ ID NO: 11 and a light chain variable region comprising a sequence selected from the group consisting of: SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17.
13. (Previously Presented) A method according to claim 10, wherein the altered anti-MAG antibody or functional fragment thereof comprises a heavy chain variable region comprising SEQ ID NO: 12 and a light chain variable region comprising a sequence selected from the group consisting of: SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17.
14. (Previously Presented) A method according to claim 10, wherein the altered anti-MAG antibody is a humanized antibody and comprises:
  - (a) a heavy chain variable region comprising a sequence selected from the group consisting of: SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12,
  - (b) a constant part of a human heavy chain or fragment thereof,
  - (c) a light chain variable region comprising a sequence selected from the group consisting of: SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17, and
  - (d) a constant part of a human light chain.
15. (Previously Presented) A method according to claim 14, wherein the humanized antibody is class IgG.
16. (Previously Presented) A method according to claim 15, wherein the humanized antibody is class IgG1.
- 17-19. (Cancelled)